The UK Office of Fair Trading has announced a review of the Pharmaceutical Price Regulation Scheme (PPRS). The scheme sets the framework for negotiations between Government and the pharmaceutical industry on the price of medicines the NHS purchases. Under the PPRS arrangements, which are voluntary and renegotiated every five years, drug company profits, as a result of sales to the NHS, are capped. The scheme also aims to maintain an incentive for pharmaceutical firms to invest in research and development. Click here for an OFT press release.
This was unexpected and caught Big Pharma on the hop!
No comments:
Post a Comment